July 23 (Reuters) – A panel of advisers to the U.S. Food and Drug Administration on Thursday voted to place a widely used peptide called BPC-157 on a list that would allow broader pharmacy compounding.
Eight panel members voted in favor, while six members voted against it. One member abstained.
(Reporting by Sriparna Roy, Sneha S K in Bengaluru, Amina Niasse in New York; Editing by Joyjeet Das)
